Clinical trials
Prostatic Cancer clinical trials
Below are recruiting prostatic cancer clinical trials, each written for real people, not researchers. We’re tracking 1,219 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04858880Recruiting
Personalized radiation for PSA rise after prostate surgery
This study tests a tailored (personalized) radiation plan for men whose PSA (“prostate blood test”) rises after prostate surgery but who have no detectable spread on scans. It may help control cancer growth by targeting the right area based on your situation.
JönköpingAges 18 years+ - NCT04861415Recruiting
Testing a shorter radiation plan versus standard prostate radiation
This study compares two ways of giving radiation to the prostate, including a “boost” using a special internal radiation treatment. It’s meant to see which radiation schedule works better and is safer for certain prostate cancer patients.
Toronto, OntarioAges 18 years+ - NCT04886986RecruitingPhase 1
Testing a targeted radiation pill for advanced prostate cancer
This Phase 1 trial tests a small-molecule treatment that carries radioactive material to help treat prostate cancer that has spread and keeps growing despite standard hormone-blocking treatment. It’s mainly looking to find a safe dose and see how well the approach works in people with limited treatment options.
Brooklyn, New YorkAges 18–99 - NCT04894188Recruiting
Hormone plus radiation before prostate surgery for high-risk cancer
This trial studies giving hormone treatment and radiation before prostate surgery to treat high-risk, locally advanced prostate cancer. It aims to improve cancer control by shrinking or controlling the tumor before removing it.
Douliu City/Huwei Township, Yunlin CountyAges 20–75 - NCT06844383RecruitingPhase 2
Talazoparib with or without enzalutamide for prostate cancer after abiraterone
This trial tests whether a drug called talazoparib, alone or combined with enzalutamide, can help people with a certain type of advanced prostate cancer that has stopped responding to abiraterone. It is for those who have a specific genetic change (HRR mutation) in their tumor.
Duarte, CaliforniaAges 18 years+ - NCT04946370RecruitingPhase 1/Phase 2
Pembrolizumab plus prostate cancer drug, with or without radiation
This early-phase trial tests pembrolizumab (an immune therapy) plus an androgen-receptor–blocking prostate cancer drug, and possibly a targeted radiation treatment. It’s for men with prostate cancer that has spread and keeps worsening despite standard hormone therapy, aiming to shrink tumors and improve control of the disease.
Boston, MassachusettsAges 18 years+ - NCT04947254RecruitingPhase 2
Add niraparib to hormone therapy after prostate radiation
This Phase 2 trial tests whether adding niraparib to standard hormone therapy (androgen ablation) after radiation works better for men with high-risk, localized or locally advanced prostate cancer. It may help control the cancer for longer, while also collecting extra tissue and blood to study why the treatment works or doesn’t.
Houston, TexasAges 18 years+ - NCT04995198Recruiting
Prostate cancer patient registry for genetics and treatment outcomes
This registry collects information from people with prostate cancer to better understand how genetics and treatments affect survival and outcomes. Your data may help researchers improve future treatment choices.
Baltimore, MarylandAges 18 years+ - NCT05019846RecruitingPhase 3
Radiation alone versus radiation plus hormone therapy for prostate cancer
This Phase 3 trial compares two treatment approaches: stereotactic radiation therapy by itself versus the same radiation plus hormone therapy (ADT). It aims to see which plan works better for men with higher-risk prostate cancer without spread to lymph nodes or distant sites.
Brescia, BSAges 18–80 - NCT05022914Recruiting
PSMA PET/CT scan for PSA relapse after prostate surgery
This trial looks at using a PSMA PET/CT scan to better re-check cancer activity in men whose PSA has started rising after prostate removal. If you qualify, the scan may help doctors choose the next best treatment step.
FlorenceAges 18 years+ - NCT05045066RecruitingEarly Phase 1
Vitamin D treatment study for Black men with prostate cancer
This early-phase study looks at how vitamin D replacement affects the immune system in Black/African American men with prostate cancer. It’s testing whether bringing vitamin D levels into a healthier range changes immune signals that may matter for cancer health.
Scottsdale, ArizonaAges 18 years+ - NCT05054296RecruitingPhase 2
Exercise and Fitbit monitoring to lower heart risk in prostate cancer
This Phase 2 study tests whether a structured exercise and lifestyle program, tracked with a Fitbit, can reduce cardiovascular (heart) risk in men with prostate cancer on hormone therapy. It also checks whether this is safe and feasible while monitoring symptoms and fitness changes.
Houston, TexasAges 18 years+ - NCT05129605Recruiting
Prostate cancer genetic risk screening study for men
This study looks at your personal and family risk for prostate cancer and helps decide who should have extra screening like MRI. It may help you find cancer earlier if you are at higher genetic risk.
Boston, MassachusettsAges 35–74 - NCT05163197Recruiting
Registry for laser treatment of localized prostate cancer
This is a registry study that collects information from men with localized prostate cancer who receive transperineal laser ablation (a procedure done through the skin between the scrotum and anus). It may help doctors better understand outcomes and refine treatment choices over time.
AmsterdamAges 18 years+ - NCT05168618RecruitingPhase 2
Cabozantinib and atezolizumab for advanced prostate cancer
This Phase 2 trial tests cabozantinib plus atezolizumab in people with metastatic prostate cancer that keeps growing despite hormone-blocking therapy and newer hormone drugs. It may help shrink tumors and control the disease, especially in advanced cases where options are limited.
Salt Lake City, UtahAges 18 years+ - NCT05223803RecruitingPhase 2
Study radiation for early metastatic prostate cancer
This Phase 2 trial tests a radiation-focused approach for people with newly diagnosed (de novo) prostate cancer that has spread to a small number of spots, especially in bone. It aims to see how well the treatment controls the cancer while keeping side effects manageable.
La Jolla, CaliforniaAges 18 years+ - NCT05225428Recruiting
Video education program based on personal genetic result disclosure
This study tests a video-based education approach that shares information differently depending on someone’s genetic test results. It may help people better understand cancer-related genetic information and what it could mean for them.
Boston, MassachusettsAges 18 years+ - NCT05241236Recruiting
Laser ablation guided by MRI and ultrasound for prostate cancer
This trial looks at a treatment that uses MRI and ultrasound to guide a laser to destroy prostate cancer. It may help men with low- or intermediate-risk prostate cancer who do not have spread beyond the prostate.
Miami Lakes, FloridaAges 50 years+ - NCT05295407Recruiting
Testing a risk assessment to predict prostate cancer on biopsy
This trial studies whether a risk assessment can better predict who actually has prostate cancer based on information collected around the biopsy. It may help doctors decide what biopsy findings mean for people with certain PSA (a blood test) results.
Evanston, IllinoisAges 40–69 - NCT05313191Recruiting
Proton therapy for tumors after prior radiation
This study looks at whether a type of proton beam treatment can be given safely and effectively to tumors that have already been treated with radiation before. It may help people whose tumors came back or persisted after earlier radiation, using a specific proton method called pencil beam scanning.
New York, New YorkAges 18 years+ - NCT05313815Recruiting
Test a stronger prostate radiation boost for high-risk prostate cancer
This trial studies whether giving a moderate “boost” dose of radiation to the prostate—along with radiation to the pelvic area—can better control high-risk localized prostate cancer. You may benefit if you have high-risk disease and can safely receive radiation.
Toronto, OntarioAges 18 years+ - NCT05328505Recruiting
Imaging-guided radiation for prostate cancer that came back
This trial tests whether a special scan (PSMA PET) can help doctors aim and adjust radiation more precisely when prostate cancer returns after surgery. It may help by increasing dose to areas that look involved while lowering dose to uninvolved pelvic areas.
London, OntarioAges 18 years+ - NCT05344235Recruiting
Study of very short radiation schedules for prostate cancer
This observational study looks at how well men with localized prostate cancer do when treated with an unusually short radiation approach. It may help doctors understand which patients benefit most by tracking outcomes and imaging over time.
Leuven, Vlaams BrabantAges Any age - NCT05346848RecruitingPhase 2
Darolutamide plus radiation for intermediate-risk prostate cancer
This trial tests whether adding darolutamide to standard radiation can better control intermediate-risk prostate cancer. It includes men whose cancer has spread nowhere else and who are newly diagnosed with “unfavorable intermediate risk” or progress to that risk group.
AvignonAges 18 years+
Hear when a new Prostatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostatic cancer?
- Yes. Clin2 currently lists 1,219 recruiting prostatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.